Securian Asset Management Inc. Sells 100 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Securian Asset Management Inc. cut its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 3.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,686 shares of the medical research company’s stock after selling 100 shares during the quarter. Securian Asset Management Inc.’s holdings in Charles River Laboratories International were worth $496,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in CRL. Versant Capital Management Inc boosted its position in Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after purchasing an additional 150 shares during the period. Assetmark Inc. boosted its holdings in shares of Charles River Laboratories International by 1,153.3% during the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after buying an additional 173 shares during the period. Pinnacle Bancorp Inc. grew its stake in Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after buying an additional 65 shares during the last quarter. Tortoise Investment Management LLC raised its holdings in Charles River Laboratories International by 77.7% in the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock valued at $49,000 after acquiring an additional 115 shares during the period. Finally, Wilmington Savings Fund Society FSB acquired a new stake in Charles River Laboratories International during the third quarter worth approximately $59,000. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Up 2.3 %

Shares of CRL opened at $175.02 on Tuesday. The firm has a 50 day simple moving average of $167.46 and a two-hundred day simple moving average of $184.33. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. Charles River Laboratories International, Inc. has a one year low of $150.79 and a one year high of $274.77. The company has a market cap of $8.95 billion, a P/E ratio of 1,166.77, a P/E/G ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International’s revenue was down 1.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.46 EPS. Research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CRL has been the subject of several research reports. Bank of America dropped their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. Robert W. Baird lowered their price objective on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a research report on Thursday, February 20th. Redburn Atlantic raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 target price for the company in a research report on Monday, March 3rd. JPMorgan Chase & Co. decreased their price target on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a research note on Thursday, February 20th. Finally, CLSA cut shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective for the company. in a research note on Monday, November 18th. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of “Hold” and an average target price of $198.36.

Insider Transactions at Charles River Laboratories International

In related news, CEO James C. Foster acquired 6,075 shares of the company’s stock in a transaction that occurred on Thursday, February 20th. The stock was acquired at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the purchase, the chief executive officer now directly owns 183,639 shares in the company, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the business’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).